Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 92 of 6351
-
New drug rilvegostomig takes on keytruda in lung cancer showdown
Disease control Recruiting nowThe purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
One shot for two viruses: new combo vaccine tested in seniors
Vaccine CompletedThe purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 08:00 UTC
-
Can a cancer drug stop leukemia before it starts?
Prevention Recruiting nowThe purpose of this study is to find out whether the study drug mogamulizumab is effective in preventing the development of adult T-cell leukemia/lymphoma (ATL) in people who are at higher risk for this type of cancer because they are infected with the HTLV-1 virus and because of…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 09:11 UTC
-
Can MDMA help couples heal from trauma together?
Disease control Recruiting nowThis study aims to evaluate the safety, feasibility, acceptability, and effectiveness of MDMA-assisted Cognitive-Behavioral Conjoint Therapy (CBCT) versus CBCT alone for the treatment of Post-Traumatic Stress Disorder (PTSD). PTSD is a debilitating condition that significantly im…
Phase 2 • Sponsor: Remedy • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Million-Person quest to catch a silent cancer early
Diagnosis Recruiting nowThe purpose of this study is to establish a comprehensive and integrated nasopharyngeal carcinoma screening cohort, which includes an epidemiological information database containing basic information, gender, age, ethnic and family history, dietary and lifestyle habits, and geogr…
Sponsor: Ming-Yuan Chen • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
New nanobody CAR t therapy targets tough leukemia
Disease control Recruiting nowTo evaluate the efficacy and safety of Nanobody-Based CD19/CD22 Tandem Dual Chimeric Antigen Receptor (CAR) T-cell therapy in patients with relapsed or refractory B-ALL
Phase 1/2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a new vaccine shield against more HPV types?
Prevention Recruiting nowResearchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For som…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Sep 04, 2026 00:00 UTC
-
New hope for kids with relapsed neuroblastoma: BEACON2 trial tests drug cocktails
Disease control Recruiting nowNeuroblastoma is one of the most common solid childhood tumours, and a major cause of cancer-related death in children. More than 1200 children/young adults a year are diagnosed in USA and Europe. Around 600 of these cases are considered high-risk, which means the cancer is more …
Phase 1/2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug could prevent eye cancer recurrence in High-Risk patients
Disease control Recruiting nowAt least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in pa…
Phase 3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could antibody shots replace daily HIV pills for kids? new trial begins in botswana
Disease control Recruiting nowThe purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of…
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could cheaper scans replace MRI for women with dense breasts?
Diagnosis Recruiting nowWomen with extremely dense breasts (nearly all glandular and connective tissue, little fatty tissue) have a 3-6 times higher risk of breast cancer than women with very low breast density. Moreover, due to the masking effect of the dense tissue, any breast tumours present are more…
Sponsor: C.H. van Gils • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
Two-Drug combo aims to cure chronic hepatitis b
Disease control OngoingThe study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced the…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a targeted pill shrink a rare, Treatment-Resistant stomach cancer?
Disease control Recruiting nowAn international multicenter, open, single-arm pivotal registration phase III study to determine the efficacy and safety of olverembatinib in patients with SDH-deficient gastrointestinal stromal tumor (GIST) who have previously been treated with one-line therapy, and to evaluate …
Phase 3 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New hope for rare leukemia: phase 3 trial of IMM01 combo launches
Disease control Recruiting nowThis study is a randomized, controlled, double-blind, multicenter, phase Ⅲ clinical study to evaluate the efficacy of IMM01(timdarpacept) in combination with azacitidine versus placebo in combination with azacitidine in patients with newly diagnosed chronic leukemia monocytic (CM…
Phase 3 • Sponsor: ImmuneOnco Biopharmaceuticals (Shanghai) Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug aims to prevent deadly bleeding in unborn babies
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness of nipocalimab compared with placebo in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy targets Brain-Attacking antibodies in severe encephalitis
Disease control Recruiting nowAutoimmune encephalitis is an autoimmune disease of the central nervous system that targets neuronal autoantigens. Anti-neuronal autoantibodies are produced in patients, with anti-NMDAR antibody being the most common.Anti-NMDAR encephalitis can be severe and life-threatening. Ant…
Phase 3 • Sponsor: The First People's Hospital of Changzhou • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Sound waves could boost brain cancer drug delivery
Disease control Recruiting nowThis will be a prospective, randomized, standard of care (SoC) controlled, parallel, open-label, multicenter pivotal study to investigate the efficacy and safety of Bevacizumab (BEV) in combination with or without microbubble (MB)-mediated FUS in patients with recurrent GBM. BEV …
Phase 3 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a daily powder cure food allergies in kids?
Cure Recruiting nowThe aim is to study whether a multiallergen oral immunotherapy (OIT) strategy with slow up-dosing and low treatment dose against food allergy in young children (0.5-3 years) is safe and effective, a method to cure food allergy and to prevent the development of new food allergies.…
Sponsor: Karolinska Institutet • Aim: Cure
Last updated Jun 26, 2026 18:28 UTC
-
One-Shot gene therapy could free hemophilia b patients from frequent injections
Disease control Recruiting nowThe aim of the study is to demonstrate non-inferiority of ANB-002 compared with preventive use of coagulation factor IX (FIX) in adult subjects with hemophilia B with FIX activity ≤2% and without FIX inhibitor. The study will have an open-label single-arm design.
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
CRISPR therapy shows promise in early trial for fatal muscle disease
Disease control OngoingDuchenne muscular dystrophin (DMD) is an X-linked, fatal muscle-wasting disease caused by mutations in the DMD gene encoding the dystrophin proteins, with symptom onset before age of 6 years in boys. These mutations abolish dystrophin production in the muscle, leading to dystroph…
Early phase 1 • Sponsor: HuidaGene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC